DGK

By Targets:	DGK (22) 5-HT Receptor (2) Apoptosis (2) ERK (1) HIV (1) Isotope-Labeled Compounds (1) PKC (3)
By Research Areas:	Cancer (23) Infection (2) Inflammation/Immunology (7) Metabolic Disease (2)

Targets Recommended: DGK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135898

DGK-IN-1

DGK Inflammation/Immunology Cancer

DGK-IN-1 is a T cell activator extracted from patent WO2020006018A1, example 25. DGK-IN-1 can be used for tumor immunity .
HY-156572

DGKζ-IN-3

Others Cancer

DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases .

DGK-IN-1	DGK	Inflammation/Immunology Cancer
DGK-IN-1 is a T cell activator extracted from patent WO2020006018A1, example 25. DGK-IN-1 can be used for tumor immunity .

DGKζ-IN-3	Others	Cancer
DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases .

HY-156573

DGKα&ζ-IN-1	DGK	Cancer
DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα&ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .

HY-156576

DGKα-IN-6

DGK Cancer

DGKα-IN-6 is a DGKα inhibitor with the IC₅₀ of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.
HY-156577

DGKα-IN-7

DGK Cancer

DGKα-IN-7 is a DGKα inhibitor with the IC₅₀ of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.
HY-160123

DGKζ-IN-5

DGK Cancer

DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a) .

DGKα-IN-6	DGK	Cancer
DGKα-IN-6 is a DGKα inhibitor with the IC₅₀ of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.

DGKα-IN-7	DGK	Cancer
DGKα-IN-7 is a DGKα inhibitor with the IC₅₀ of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.

DGKζ-IN-5	DGK	Cancer
DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a) .

HY-156574

DGKζ-IN-4	DGK	Cancer
DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody treatment .

HY-156569

DGKα-IN-2	DGK	Inflammation/Immunology Cancer
DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC₅₀ of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.

HY-156570

DGKα-IN-3	DGK	Inflammation/Immunology Cancer
DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC₅₀ of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.

HY-156571

DGKα-IN-4	DGK	Cancer
DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC₅₀ of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.

HY-153793

DGKζ-IN-1	DGK	Cancer
DGKζ-IN-1 (compound 9) is an inhibitor of DGKζ. DGKζ-IN-1 can be used for research in cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody .

HY-156578

DGKα-IN-8	DGK HIV	Infection Cancer
DGKα-IN-8 (Example 51) is a DGKα inhibitor (IC₅₀=22.491 nM; EC₅₀=0.256 nM). DGKα-IN-8 can be used to study cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection .

HY-156575S

DGKα-IN-5

Isotope-Labeled Compounds Others

DGKα-IN-5 is a deuterium labeled compound.

DGKα-IN-5	Isotope-Labeled Compounds	Others
DGKα-IN-5 is a deuterium labeled compound.

HY-121638

CU-3	Apoptosis DGK	Inflammation/Immunology Cancer
CU-3 is the racemate of (5Z,2E)-CU-3. (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of *DGK* with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .

HY-149874

BMS-502	DGK	Inflammation/Immunology
BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC₅₀ of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .

HY-149665

BMS-684	DGK	Cancer
BMS-684 is a selective DGKα inhibitor with an IC₅₀ of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes .

HY-149667

BMS-332

DGK Cancer

BMS-332 is adualDGKα/ζlipid kinase inhibitor, with theIC₅₀of 0.005 (DGKα) and 0.001 μM (DGKζ) .
HY-149666

BMS-496

DGK Cancer

BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC₅₀of 0.09 (DGKα) and 0.006 μM (DGKζ) .

BMS-332	DGK	Cancer
BMS-332 is adualDGKα/ζlipid kinase inhibitor, with theIC₅₀of 0.005 (DGKα) and 0.001 μM (DGKζ) .

BMS-496	DGK	Cancer
BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC₅₀of 0.09 (DGKα) and 0.006 μM (DGKζ) .

HY-108355

R59949	PKC	Cancer
R59949 is a pan diacylglycerol kinase (DGK) inhibitor with an IC₅₀ of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol .

HY-156567

AMB639752	DGK	Metabolic Disease
AMB639752 is a potent DGKα inhibitor. AMB639752 restores restimulation induced cell death (RICD) in SAP deficient lymphocytes by inhibiting DGKα in intact cells. AMB639752 can be used for X-linked lymphoproliferative disease 1(XLP-1) research .

HY-100960

Dioctanoylglycol Ethylene glycol dicaprylate; Ethylene glycol dioctanoate; Ethylenedioctanoate
Dioctanoylglycol (Ethylene glycol dicaprylate), a diacylglycerol analog, is a diacylglycerol kinase (DGK) inhibitor (K_i of 58 μM) .

HY-121638A

(5Z,2E)-CU-3 1 Publications Verification	Apoptosis DGK	Cancer
(5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of *DGK* with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .

HY-153343

BAY 2965501	DGK	Cancer
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .

HY-122949

Momordicine I	DGK	Metabolic Disease
Momordicine I, a triterpenoid compound extracted from momordica charantia L. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ .

HY-153343A

(S)-BAY 2965501	DGK ERK	Cancer
(S)-BAY 2965501 is the left-handed isomer of BAY 2965501 (HY-153343). BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .

HY-148174

JNJ-3790339	DGK	Cancer
JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective *diacylglycerol kinase (DGKα)* inhibitor with an IC₅₀ of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation .

HY-N0097A

9-β-D-Arabinofuranosylguanine AraG	Others	Cancer
9-β-D-Arabinofuranosylguanine is a Guanosine (HY-N0097) analog and shows high affinity for deoxyguanosine kinase (dGK) with a K_m of 8.0 μM. 9-β-D-Arabinofuranosylguanine can be used for the research of T-cell lymphoblastic disease .

HY-107613

R 59-022 1 Publications Verification DKGI-I; Diacylglycerol kinase inhibitor I	PKC 5-HT Receptor	Inflammation/Immunology
R 59-022 (DKGI-I) is a *DGK* inhibitor (IC₅₀: 2.8 µM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .

HY-107613A

R 59-022 hydrochloride 1 Publications Verification DKGI-I hydrochloride; Diacylglycerol kinase inhibitor I hydrochloride	PKC 5-HT Receptor	Infection Inflammation/Immunology Cancer
R 59-022 (DKGI-I) hydrochloride is a *DGK* inhibitor (IC₅₀: 2.8 µM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-122949

Momordicine I	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Momordica charantia Linn.	DGK
Momordicine I, a triterpenoid compound extracted from momordica charantia L. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ .

Species:	Human (2)
Tag:	SUMO (1) His (2) Myc (2)
Source:	E. coli Cell-free (1) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702262

	DGKE Protein, Human (Cell-Free, His, SUMO, Myc) Diacylglycerol kinase epsilon; Diglyceride kinase epsilon; DGK-epsilon	Human	E. coli Cell-free
	DGKE protein is a membrane-bound diacylglycerol kinase that balances cell signaling by converting diacylglycerol (DAG) to phosphatidic acid (PA). As a central switch in signaling pathways, DGKE has opposite effects on various biological processes and significantly promotes complex lipid biosynthesis. DGKE Protein, Human (Cell-Free, His, SUMO, Myc) is the recombinant human-derived DGKE protein, expressed by E. coli Cell-free , with N-10*His, C-Myc, N-SUMO labeled tag. The total length of DGKE Protein, Human (Cell-Free, His, SUMO, Myc) is 567 a.a., with molecular weight of 83.9 kDa.

HY-P702617

	DGKA Protein, Human (sf9, His, Myc) 80 kDa diacylGlycerol kinase; DAG kinase alpha; DAGK; DAGK1; DGK alpha; DGK-alpha; DGKA; DGKA_HUMAN; DiacylGlycerol kinase alpha; DiacylGlycerol kinase; alpha 80kDa; Diglyceride kinase alpha; MGC12821; MGC42356; OTTHUMP00000242836; OTTHUMP00000242955; OTTHUMP00000244046	Human	Sf9 insect cells


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-156575S

DGKα-IN-5

DGKα-IN-5 is a deuterium labeled compound.

DGKα-IN-5
DGKα-IN-5 is a deuterium labeled compound.

Cat. No.	Product Name	Application	Reactivity

HY-P83116

DGKA Antibody (YA2861)

DAGK; DAGK1; DGK-alpha
WB, IHC-P, IP Human
HY-P81477

DGKZ Antibody (YA1222)

DAGK5; DAGK6; DGK-ZETA; hDGKzeta
IHC-P Human

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

DGK

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products